Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 3/2010

01-05-2010 | Clinical Trial Report

Prognostic and Predictive Factors in the Targeted Therapy Era: Filling in the Blanks

Author: Eric Jonasch

Published in: Current Oncology Reports | Issue 3/2010

Login to get access

Excerpt

Heng DY, Xie W, Regan MM, et al.: Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009, 27:5794–5799. …
Literature
1.
Motzer RJ, Mazumdar M, Bacik J, et al.: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999, 17:2530–2540.PubMed
2.
Motzer RJ, Bacik J, Murphy BA, et al.: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20:289–296.CrossRefPubMed
3.
Huang D, Ding Y, Zhou M, et al.: Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010, 70:1063–1071.CrossRefPubMed
4.
Tsavachidou-Fenner D, Tannir N, Tamboli P, et al.: Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma. Ann Oncol 2010 Jan 20 (Epub ahead of print).
5.
Klatte T, Rao PN, de Martino M, et al.: Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol 2009, 27:746–753.CrossRefPubMed
6.
Schneider BP, Wang M, Radovich M, et al.: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008, 26:4672–4678.CrossRefPubMed
7.
Shojaei F, Wu X, Malik AK, et al.: Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007, 25:911–920.CrossRefPubMed
8.
Zurita AJ, Jonasch E, Wu HK, et al.: Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma. Cancer 2009, 115(10 Suppl):2346–2354.CrossRefPubMed
9.
Jensen TO, Schmidt H, Moller HJ, et al.: Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol 2009, 27:3330–3337.CrossRefPubMed
Metadata
Title
Prognostic and Predictive Factors in the Targeted Therapy Era: Filling in the Blanks
Author
Eric Jonasch
Publication date
01-05-2010
Publisher
Current Science Inc.
Published in
Current Oncology Reports / Issue 3/2010
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-010-0098-z

Other articles of this Issue 3/2010

Current Oncology Reports 3/2010 Go to the issue

ReviewPaper

Proton Beam Radiation Therapy for Head and Neck Malignancies

ReviewPaper

Novel Perspectives for the Treatment of Gastric Cancer: From a Global Approach to a Personalized Strategy

ReviewPaper

Renal Cell Carcinoma: Where Will the State-of-the-Art Lead Us?

ReviewPaper

KRAS Testing and Its Importance in Colorectal Cancer

ReviewPaper

Advances in Quality of Life Research Among Head and Neck Cancer Patients

ReviewPaper

Current and Emerging Treatment Strategies for Anal Cancer

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits